Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.
$CLOV
Medical Specialities
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $6.00 | Buy | Craig Hallum |
| 10/7/2024 | $4.00 | Neutral | UBS |
| 2/25/2022 | $3.00 → $2.50 | Market Perform | SVB Leerink |
| 2/2/2022 | $7.00 → $3.00 | Underperform → Market Perform | Cowen & Co. |
| 2/2/2022 | $6.00 | Buy | Canaccord Genuity |
| 1/19/2022 | $3.00 | Market Perform | SVB Leerink |
| 1/10/2022 | $9.00 → $3.50 | Neutral | Citigroup |
| 1/7/2022 | $9.00 → $3.50 | Neutral → Underperform | Credit Suisse |
Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-yearAchieved industry-leading 2026 AEP growth of 53% year-over-year with strong returning member retentionExpect improving cohort economics powered by Clover Assistant to drive our first-ever full year of GAAP Net Income profitability in 2026 Financial Results: Full year 2025 Medicare Advantage membership of 113,803, up 38% year-over-yearFull year 2025 Total revenues of $1.9 billion, up 40% year-over-yearFull year 2025 GAAP Net loss of $86 million, Adjusted EBITDA of $22 million, and Adjusted Net Income of $20 million Full Year 2026 Gu
WILMINGTON, Del., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Leerink 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 9:20 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A session will be accessible on Clover Health's investor relations website at https://investors.cloverhealth.com/. About Clover Health:Clover Health (NASDAQ:CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors wh
WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Thursday, February 26, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Fourth Quarter and Full Year 2025 Conference Webcast Details: What: Clover Health's Fourth Quarter and Full Year 2025 Earnings Conference CallWhen: Thursday, February 26, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00
UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00
SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
144 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-yearAchieved industry-leading 2026 AEP growth of 53% year-over-year with strong returning member retentionExpect improving cohort economics powered by Clover Assistant to drive our first-ever full year of GAAP Net Income profitability in 2026 Financial Results: Full year 2025 Medicare Advantage membership of 113,803, up 38% year-over-yearFull year 2025 Total revenues of $1.9 billion, up 40% year-over-yearFull year 2025 GAAP Net loss of $86 million, Adjusted EBITDA of $22 million, and Adjusted Net Income of $20 million Full Year 2026 Gu
WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Thursday, February 26, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Fourth Quarter and Full Year 2025 Conference Webcast Details: What: Clover Health's Fourth Quarter and Full Year 2025 Earnings Conference CallWhen: Thursday, February 26, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https
Business Highlights: Generates third quarter year-to-date positive Adjusted EBITDA profitability, on a wide network, while growing membership by 35% and revenue by 39% year-over-year, despite a greater proportion of new members relative to returning member baseHigh coverage of Clover Assistant, including within new cohorts, will result in improved total cost of care Strong retention, above-market growth, and profitable returning member cohorts position Clover for improved positive FY26 Financial Results Financial Results: Third quarter 2025 Medicare Advantage membership of 109,226, up 35% year-over-yearThird quarter 2025 Total revenues of $497 million, up 50% year-over-yearThird quarter 2
WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today celebrates the appointment of Dr. Ian Duncan, Ph.D., FSA, FIA, FCIA, FCA, CSPA MAAA, a member of Clover's Medicare Advantage Board of Directors, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). On September 12, 2025, the SOA announced that Dr. Duncan will become the 78th President and Chair at the 2026 SOA ImpACT Annual Conference. With roots dating back to 1889, the SOA is the world's largest actuarial
WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations. As Counterpart scales to meet growing demand from payors and providers nationwide, Bruner will lead several critical functions including customer implementations, provider network engagement, clinician onboarding and training, and longitudinal account support. Her work will be foundational, ensuring operational readiness and delivery consisten
WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function. Mr. Oldakowski, who joined Clover Health in June, brings nearly two decades of experience in finance and accounting leadership across the healthcare and insurance sectors. He most recently served a
The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso